Afaxys

Executive Summary

Afaxys Pharma is a US-based generic pharmaceutical company focused on reproductive and sexual healthcare, serving community and public health providers. Founded in 2010 and headquartered in Charleston, South Carolina, the company offers a broad portfolio of generic contraceptives, including oral contraceptives, an emergency contraceptive, a contraceptive patch, and a local anesthetic. Its mission-driven approach aims to ensure reliable and affordable access to these essential products, particularly for underserved populations. As a private, mission-oriented entity, Afaxys is well-positioned to benefit from increasing policy support for reproductive health access and generic drug utilization. The company's Phase 3 stage suggests ongoing development or expansion of its product line, potentially including new generic entrants or formulations. With a focus on affordability and public health partnerships, Afaxys is poised for steady growth in the generic contraceptive market, which is driven by consistent demand and favorable demographic trends. However, as a private company, financial details and pipeline specifics are limited, making near-term visibility moderate.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of a new generic contraceptive product70% success
• Q2 2026Expansion of public health distribution partnerships80% success
• TBDLaunch of an additional generic product in adjacent therapeutic area50% success